The International Myopia Institute released their Volume 1 of reports in 2019 and Volume 2 in 2021. Here, we explore the latest round of reports in 2021 and what they each mean for clinical practice.
Myopia is becoming more common, as knowledge on detection and management increase. When should you start myopia control? Here we present an overview of when you might start myopia management across the spectrum of patient presentations. Since every child and their family are unique, we also point you towards more information for each situation.
Most clinicians are aware of myopia risk factors such as family history and visual environment, but how about axial length? This article explores how we can use the current axial length value, change in axial length, axial length growth charts, and another metric, the axial-length-to-corneal-radius (AL/CR ratio), to predict risk of a child developing myopia.
What does on-label and off-label prescribing mean in myopia management? Here we explore this topic from the point of view of medications and medical devices, what regulatory approvals mean and how this applies to decision making and clinical processes such as informed consent.
The COVID-19 pandemic saw widespread home confinement, increased screen time in children with home-based learning, and decreased time spent outdoors. Several recent publications have explored the impact of this period of time on the incidence and progression of myopia, lifestyle behaviours, digital eye strain, myopia treatment efficacy and more. What should we now monitor and discuss with our young myopic patients in the post-COVID world?
How can we identify pseudomyopia? The IMI defines myopia as -0.50D or more when accommodation is relaxed. Yet recent data indicates that a quarter of 6-year-olds may present as myopic when they’re in fact exhibiting pseudomyopia. Explore more on this topic and how to relax accommodation for accurate refractions in children.
Most atropine currently prescribed for myopia control is compounded rather than being commercially mass manufactured. How could this influence research results and clinical outcomes? Learn more about compounded topical atropine including questions to ask your compounding pharmacist.
Atropine is a treatment for myopia control, but do combination treatments such as with orthokeratology increase the efficacy? Learn about how well it works, which concentration, for whom it works best, side effects, treatment duration and more.
In 2021, the World Council of Optometry (WCO) passed a resolution that publicly declares support for myopia management as standard of care. Since then, CooperVision has supported the WCO to empower eye care professionals to put this into action, with a multilingual online resource launched and more being added throughout 2022. Explore and learn more here.
Adults with myopia may not understand that they have more than just a problem seeing clearly. We discuss genetic risk in glaucoma and macular degeneration – are you doing the same for myopia? How can we talk to myopic adults about risks for their children and support them to take action?
